(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.64% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 121.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.88%.
Zoetis's revenue in 2025 is $9,385,000,000.On average, 20 Wall Street analysts forecast ZTS's revenue for 2025 to be $4,259,879,532,864, with the lowest ZTS revenue forecast at $4,106,981,235,024, and the highest ZTS revenue forecast at $4,444,243,857,216. On average, 19 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,510,721,378,016, with the lowest ZTS revenue forecast at $4,316,607,017,280, and the highest ZTS revenue forecast at $4,765,551,874,416.
In 2027, ZTS is forecast to generate $4,766,438,241,360 in revenue, with the lowest revenue forecast at $4,484,130,369,696 and the highest revenue forecast at $5,133,837,339,648.